NOXXON secures EUR6.2m equity capital raise
NOXXON Pharma, a biotechnology company focussed on improving cancer treatments by targeting the tumour microenvironment (TME), has secured an equity capital raise totalling EUR6.2 million, including USD5 million committed by lead investor, Acuitas Capital, LLC, a US based family office. This equity capital raise meets the criteria to end YA
